PP
CRSP icon

Paloma Partners’s CRISPR Therapeutics CRSP Stock Holding History

Paloma Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,324
Closed -$264K – 1390
2019
Q4 		$264K Buy
+4,324
New +$236K ﹤0.01% 1832
2018
Q1 		– Sell
-12,360
Closed -$290K – 1999
2017
Q4 		$290K Buy
+12,360
New +$235K ﹤0.01% 1576

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Paloma Partners's CRSP Position: Q1 2020 in Review

Paloma Partners sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 4,324 shares — an estimated $264K sold.

Paloma Partners first reported a position in CRSP in Q4 2017 and held it in 2 quarters. The position peaked at $290K in Q4 2017. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

  • Paloma Partners reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Paloma Partners sold 4,324 CRISPR Therapeutics shares in Q1 2020, an estimated $264K.
  • Paloma Partners first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 2 quarters.
  • Paloma Partners's CRISPR Therapeutics position peaked at $290K in Q4 2017.
  • 257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.